CCM
AEGR

Cupps Capital Management’s Aegerion Pharmaceuticals AEGR Stock Holding History

Cupps Capital Management’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-277,097
Closed -$19.7M – 226
2013
Q4 		$19.7M Sell
277,097
-13,392
-5% -$1.02M 1.34% 20
2013
Q3 		$24.9M Buy
290,489
+1,626
+0.6% +$138K 1.61% 17
2013
Q2 		$18.3M Buy
+288,863
New +$15.3M 1.46% 22

Other funds holding AEGR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return

Cupps Capital Management's AEGR Position: Q1 2014 in Review

Cupps Capital Management sold out of Aegerion Pharmaceuticals (AEGR) in Q1 2014, closing a stake of 277,097 shares — an estimated $19.7M sold.

Cupps Capital Management first reported a position in AEGR in Q2 2013 and held it in 3 quarters. The position peaked at $24.9M in Q3 2013. 131 funds tracked by Wall St. Rank hold AEGR as of Q1 2014.

  • Cupps Capital Management reported no remaining Aegerion Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Cupps Capital Management sold 277,097 Aegerion Pharmaceuticals shares in Q1 2014, an estimated $19.7M.
  • Cupps Capital Management first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • Cupps Capital Management's Aegerion Pharmaceuticals position peaked at $24.9M in Q3 2013.
  • 131 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q1 2014.

Based on Cupps Capital Management's 13F filing for Q1 2014, filed 12 May 2014.